Hull Hans
Chief Business Officer at PLRX; SVP, Business Operations at Avalanche Biotechnologies, Inc.
- Sold, on record
- $3.1M
- Dollars the filings state
- Form 4 sales
- 10
- Latest Jan 17, 2025
- Form 144 notices
- 1
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- PLRXPLIANT THERAPEUTICS, INC.Chief Business Officer
- Avalanche Biotechnologies, Inc.SVP, Business Operations
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- PLRX104,462 shares
- Avalanche Biotechnologies, Inc.34,500 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale PLRXPlan not statedDec 20, 2022 2022
Sold 8,748 shares at $19.10 ($167k)
Hull Hans, Chief Business Officer
Sold 6% of holdings ($2.8M position)138,191 shares leftFirst sale on recordFiling
- 2 Form 4 sale PLRXRoutineMar 30, 2023 +100 days
Sold 9,036 shares at $26.52 ($240k)
Hull Hans, Chief Business Officer
10b5-1 planSold 4.3% of holdings ($5.6M position)201,964 shares leftFiling
- 3 Form 4 sale PLRXRoutineJul 17, 2023 +109 days
Sold 17,937 shares at $18.01 ($323k)
Hull Hans, Chief Business Officer
10b5-1 planSold 7.6% of holdings ($4.3M position)219,183 shares leftFiling
- 4 Form 144 notice PLRXNoticeAug 3, 2023 +17 days
Filed to sell 34,919 shares ($660k)
Hull Hans, Officer
10b5-1 plan3.9x usual sizeFiling
- 5 Form 4 sale PLRXUnusualAug 4, 2023 +1 day
Sold 33,119 shares at $20.01 ($663k)
Hull Hans, Chief Business Officer
10b5-1 planSold 14.5% of holdings ($4.6M position)194,855 shares left3.7x usual sizeFollows a Form 144Filing
- 6 Form 4 sale PLRXRoutineJan 17, 2024 +166 days
Sold 9,786 shares at $17.23 ($169k)
Hull Hans, Chief Business Officer
10b5-1 planSold 5% of holdings ($3.4M position)185,069 shares left0.7x usual sizeFiling
- 7 Form 4 sale PLRXRoutineJul 10, 2024 +175 days
Sold 9,900 shares at $11.56 ($114k)
Hull Hans, Chief Business Officer
10b5-1 planSold 4.2% of holdings ($2.7M position)227,494 shares left1x usual sizeFiling
- 8 Form 4 sale PLRXRoutineJan 17, 2025 +191 days
Sold 15,936 shares at $11.20 ($178k)
Hull Hans, Chief Business Officer
10b5-1 planSold 7% of holdings ($2.5M position)211,558 shares left1.6x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (11)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jan 17, 2025 | Jan 22, 2025 | PLRX | Chief Business Officer | Form 4 sale | 15,936 | $178k | 7.0% | Routine | SEC |
| Jul 10, 2024 | Jul 12, 2024 | PLRX | Chief Business Officer | Form 4 sale | 9,900 | $114k | 4.2% | Routine | SEC |
| Jan 17, 2024 | Jan 19, 2024 | PLRX | Chief Business Officer | Form 4 sale | 9,786 | $169k | 5.0% | Routine | SEC |
| Aug 4, 2023 | Aug 7, 2023 | PLRX | Chief Business Officer | Form 4 sale | 33,119 | $663k | 14.5% | Unusual | SEC |
| Aug 3, 2023 | Aug 3, 2023 | PLRX | Officer | Form 144 notice | 34,919 | $660k | Notice | SEC | |
| Jul 17, 2023 | Jul 19, 2023 | PLRX | Chief Business Officer | Form 4 sale | 17,937 | $323k | 7.6% | Routine | SEC |
| Mar 30, 2023 | Apr 3, 2023 | PLRX | Chief Business Officer | Form 4 sale | 9,036 | $240k | 4.3% | Routine | SEC |
| Dec 20, 2022 | Dec 21, 2022 | PLRX | Chief Business Officer | Form 4 sale | 8,748 | $167k | 6.0% | Plan not stated | SEC |
| Jun 4, 2015 | Jun 5, 2015 | Avalanche Biotechnologies, Inc. | SVP, Business Operations | Form 4 sale | 2,000 | $75k | 15.0% | Plan not stated | SEC |
| May 4, 2015 | May 6, 2015 | Avalanche Biotechnologies, Inc. | SVP, Business Operations | Form 4 sale | 5,000 | $154k | 30.6% | Unusual | SEC |
| Apr 7, 2015 | Apr 8, 2015 | Avalanche Biotechnologies, Inc. | SVP, Business Operations | Form 4 sale | 27,500 | $1.1M | 89.2% | Unusual | SEC |